Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
Gene mutations linked with death from infection in patients with chronic lymphocytic leukemia
8 April 2021COVID-19 patient receives lung transplant from living donors
8 April 2021Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
